News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
This surpasses the number of approvals supported in 2020
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The drug is priced at Rs 2000 for a course of 40 tablets
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Subscribe To Our Newsletter & Stay Updated
